Regen BioPharma (RGBP) 10-Q 29 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2019	Aug. 26, 2019
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	0001589150
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity File Number	333-191725
Entity Common Stock, Shares Outstanding		571,484,406
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
CURRENT ASSETS
Cash	$ 15,090	$ 8,019
Accounts Receivable, Related Party	16,035	0
Note Receivable, Related Party	0	4,551
Note Receivable	0	0
Prepaid Expenses	101	8,259
Accrued Interest Receivable	0	7,672
Prepaid Rent	0	14,270
Total Current Assets	31,226	42,771
OTHER ASSETS
Investment Securities	12,667	166,247
Total Other Assets	12,667	166,247
TOTAL ASSETS	43,893	209,018
Current Liabilities:
Bank Overdraft	266	203
Accounts payable	78,707	80,567
Notes Payable, Related Party	8,727	227
Accrued payroll taxes	4,241	4,241
Accrued Interest	390,251	292,094
Accrued Rent	0	0
Accrued Payroll	806,158	655,663
Other Accrued Expenses	41,423	41,243
Due to Investor	20,000	20,000
Derivative Liability	5,679,959	6,736,607
Convertible Notes Payable Less $347,041 of unamortized discount	942,397	774,666
Unearned Income	0	68,000
Total Current Liabilities	7,972,129	8,673,511
Long Term Liabilities:
Convertible Notes Payable less $680,138 of unamortized discount	804,762	656,272
Convertible Notes Payable, Related Parties Less $272,026 of unamortized discount	89,474	906
Total Long Term Liabilities	894,236	657,178
Total Liabilities	8,866,365	9,330,689
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 180,315,107 issued and outstanding as of September 30, 2018 and 1,800,000,000 authorized and 377,115,053 shares issued and outstanding March 31, 2019	37,710	18,030
Additional Paid in capital	7,848,424	7,517,888
Contributed Capital	728,658	728,658
Retained Earnings (Deficit)	(17,459,047)	(17,457,044)
Accumulated Other Comprehensive Income	0	52,948
Shareholders Equity Regen Biopharma	(8,825,406)	(9,121,671)
Non Controlling Interest KCL Therapeutics	2,934	0
Total Stockholders' Equity (Deficit)	(8,822,472)	(9,121,671)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	43,893	209,018
Series A Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT)
Series A Preferred 300,000,000 authorized, 140,434,496 and 150,434,496 outstanding as of September 30, 2018 and March 31, 2019	15,044	14,044
Series AA Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT)
Series AA Preferred $0.0001 par value 600,000 authorized and 50, 000 and 50,000 outstanding as of March 31, 2019 and September 30, 2018, respectively	5
Series M
STOCKHOLDERS' EQUITY (DEFICIT)
Series M Preferred $0.0001 par value 300,000,000 authorized and and 38,000,000 outstanding as of September 30, 2018 and March 31, 2019 respectively	$ 3,800	$ 3,800

CONSOLIDATED CONDENSED BALANC_2

CONSOLIDATED CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Unamortized discount, current	$ 347,041
Unamortized discount, non-current	680,138
Unamortized discount related party	$ 272,026
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,800,000,000	500,000,000
Common stock, shares issued	377,115,053	180,315,107
Common stock, shares outstanding	377,115,053	180,315,107
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	150,434,496	140,434,496
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares outstanding	50,000	50,000
Series M
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	38,000,000	38,000,000

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
REVENUES
Revenues, Related Party	$ 27,425	$ 0	$ 54,849	$ 0
COST AND EXPENSES
Research and Development	1,346	71,948	7,940	620,033
General and Administrative	126,514	220,305	285,416	398,241
Consulting and Professional Fees	115,357	140,419	161,120	278,983
Rent	15,000	15,000	30,000	30,000
Total Costs and Expenses	258,217	447,672	484,476	1,327,257
OPERATING INCOME (LOSS)	(230,793)	(447,672)	(429,627)	(1,327,257)
OTHER INCOME & (EXPENSES)
Interest Income	0	3,881	1,302	9,544
Loss on Sale of Securities	0	0	(57,697)	0
Unrealized Gain(Loss) Investment Securities	(62,363)	0	(59,147)	0
Interest Expense	(66,628)	(65,145)	(138,575)	(130,475)
Refunds of amounts previously paid	115	0	115	0
Interest Expense attributable to Amortization of Discount	(301,830)	(324,384)	(678,100)	(652,036)
Loss on Early Extinguishment Convertible Debt	0	(41,566)	0	(41,566)
Bad Debt Expense	(118,121)	0	(118,121)	0
Derivative Income (Expense)	447,381	(255,968)	1,395,714	(1,774,213)
TOTAL OTHER INCOME (EXPENSE)	(101,446)	(683,181)	345,492	(2,588,746)
NET INCOME (LOSS)	(332,238)	(1,130,853)	(84,135)	(3,916,003)
Less:Net (Income) Loss attributable to KCL, Therapeutics, Inc.	(2,500)	0	(2,500)	0
NET INCOME (LOSS) attributable to common shareholders	$ (334,738)	$ (1,130,853)	$ (86,635)	$ (3,916,003)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0011)	$ (0.0078)	$ (0.0003)	$ (0.0269)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	295,684,600	145,343,881	255,155,894	145,814,742

CONDENSED CONSOLIDATED STATEME

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDER'S DEFICIT EQUITY (Unaudited) - USD ($)	Series A Preferred	Series AA Preferred Stock	Common Stock	Series M Preferred Stock	Additional Paid-In Capital	Retained Earnings	Contributed Capital	Accumulated Other Comprehensive	Noncontrolling Interest	Total
Beginning balance, Shares at Sep. 30, 2017	136,966,697	50,000	139,704,157	32,000,000
Beginning balance, Amount at Sep. 30, 2017	$ 13,697	$ 5	$ 13,969	$ 3,200	$ 6,642,979	$ (12,741,843)	$ 728,658	$ 88,000	$ 0	$ (5,251,335)
Common Shares issued to Consultant, Shares			2,500,000
Common Shares issued to Consultant, Amount			$ 250		109,500					109,750
Preferred Shares issued to Consultant, Shares				2,000,000
Preferred Shares issued to Consultant, Amount				$ 200						200
Preferred Shares issued to Consultant, Shares				4,000,000
Preferred Shares issued to Consultant, Amount				$ 400						400
Common Shares issued for Debt, Shares			3,976,852
Common Shares issued for Debt, Amount			$ 398		85,502					85,900
Unrealized Gain (Loss) on Securities Available for Sale								40,000		40,000
Net Income (loss)						(2,785,149)				(2,785,149)
Ending balance, Shares at Dec. 31, 2017	136,966,697	50,000	146,181,009	38,000,000
Ending balance, Amount at Dec. 31, 2017	$ 13,697	$ 5	$ 14,617	$ 3,800	6,837,981	(15,526,990)	728,658	128,000	0	(7,800,232)
Common Shares issued to Consultant, Shares			250,000
Common Shares issued to Consultant, Amount			$ 25		7,900					7,925
Common Shares issued for Debt, Shares			332,955
Common Shares issued for Debt, Amount			$ 33		10,376					10,409
Preferred Shares Purchased for Cash, Shares	2,500,000
Preferred Shares Purchased for Cash, Amount	$ 250				24,750					25,000
Common Shares Purchased for Cash, Shares			2,500,000
Common Shares Purchased for Cash, Amount			$ 250		24,750					25,000
Common Shares issued for Debt, Shares			522,255
Common Shares issued for Debt, Amount			$ 52		13,560					13,612
Common Shares issued for Debt, Shares			796,254
Common Shares issued for Debt, Amount			$ 80		18,862					18,942
Common Shares issued for Debt, Shares			744,948
Common Shares issued for Debt, Amount			$ 74		12,613					12,687
Unrealized Gain (Loss) on Securities Available for Sale								(19,200)		(19,200)
Net Income (loss)						(840,851)				(840,851)
Ending balance, Shares at Mar. 31, 2018	139,466,697	50,000	151,327,421	38,000,000
Ending balance, Amount at Mar. 31, 2018	$ 13,947	$ 5	$ 15,131	$ 3,800	6,950,792	(16,367,844)	728,658	108,800	0	(8,546,711)
Beginning balance, Shares at Sep. 30, 2018	140,434,496	50,000	180,315,107	38,000,000
Beginning balance, Amount at Sep. 30, 2018	$ 14,044	$ 5	$ 18,030	$ 3,800	7,517,888	(17,457,044)	728,658	52,948	0	(9,121,671)
Shares issued for debt, Shares			5,128,205
Shares issued for debt, Amount			$ 513		29,487					30,000
Shares issued for debt, Shares			8,961,988
Shares issued for debt, Amount			$ 896		29,754					30,650
Shares issued for debt, Shares			2,019,140
Shares issued for debt, Amount			$ 202		7,410					7,612
Shares issued for debt, Shares			3,015,618
Shares issued for debt, Amount			$ 302		11,066					11,368
Shares issued for debt, Shares			7,100,591
Shares issued for debt, Amount			$ 710		29,290					30,000
Shares issued for debt, Shares			29,033,181
Shares issued for debt, Amount			$ 2,903		47,813					50,716
Shares issued for expenses, Shares			286,232
Shares issued for expenses, Amount			$ 29		471					500
Shares issued for debt, Shares			5,184,674
Shares issued for debt, Amount			$ 518		9,929					10,447
Shares issued for expenses, Shares			617,283
Shares issued for expenses, Amount			$ 62		438					500
Shares issued for debt, Shares			10,382,717
Shares issued for debt, Amount			$ 1,038		7,372					8,410
Derecognition of Accumulated Other Comprehensive Income						52,948		(52,948)		0
Adjustment for Adoption ASU						29,186				29,186
Net Income (loss)						248,103				248,103
Ending balance, Shares at Dec. 31, 2018	140,434,496	50,000	252,044,737	38,000,000
Ending balance, Amount at Dec. 31, 2018	$ 14,044	$ 5	$ 25,203	$ 3,800	7,690,918	(17,126,807)	728,658	0	0	(8,664,180)
Shares issued for debt, Shares			10,585,123
Shares issued for debt, Amount			$ 1,059		12,692					13,751
Shares issued for services, Shares	10,000,000
Shares issued for services, Amount	$ 1,000				48,000					49,000
Shares issued for debt, Shares			5,774,947
Shares issued for debt, Amount			$ 577		6,555					7,132
Shares issued for debt, Shares			12,222,690
Shares issued for debt, Amount			$ 1,222		5,744					6,966
Shares issued for debt, Shares			10,473,668
Shares issued for debt, Amount			$ 1,047		11,887					12,934
Shares issued for debt, Shares			13,821,193
Shares issued for debt, Amount			$ 1,382		14,374					15,756
Shares issued for debt, Shares			13,790,783
Shares issued for debt, Amount			$ 1,379		18,341					19,720
Shares issued for expenses, Shares			877,310
Shares issued for expenses, Amount			$ 88		412					500
Shares issued for debt, Shares			8,004,463
Shares issued for debt, Amount			$ 800		7,844					8,644
Shares issued for expenses, Shares			694,508
Shares issued for expenses, Amount			$ 69		431					500
Shares issued for debt, Shares			14,305,492
Shares issued for debt, Amount			$ 1,431		8,868					10,299
Shares of subsidiary issued for services, Amount					441					441
Shares issued for expenses, Shares			833,449
Shares issued for expenses, Amount			$ 83		417					500
Shares issued for debt, Shares			27,377,166
Shares issued for debt, Amount			$ 2,738		19,766					22,504
Shares issued for debt, Shares			6,309,524
Shares issued for debt, Amount			$ 631		4,669					5,300
Adjustment for noncontrolling Interest KCL Therapeutics, Inc					(2,934)				2,934	0
Net Income (loss)						(332,238)				(332,238)
Ending balance, Shares at Mar. 31, 2019	150,434,496	50,000	377,115,053	38,000,000
Ending balance, Amount at Mar. 31, 2019	$ 15,044	$ 5	$ 37,710	$ 3,800	$ 7,848,424	$ (17,459,047)	$ 728,658	$ 0	$ 2,934	$ (8,822,472)

CONSOLIDATED CONDENSED STATEM_2

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ (84,135)	$ (3,916,003)
Adjustments to reconcile net Income to net cash
Preferred Stock issued to Consultants	49,000	600
Common Stock issued to consultants	0	132,164
Common Stock issued for interest	0	5,888
Subsidiary Stock issued to consultants	46	0
Subsidiary Stock issued as compensation	294	0
Common Stock issued for Expenses	2,500	0
Increase (Decrease) in Interest expense attributable to amortization of Discount	678,100	652,036
(Gain) Loss on Sale of Investment Securities	57,697	0
Increase(Decrease) in Loss on early extinguishment of debt	0	41,566
Changes in operating assets and liabilities:
Unrealized (Gain) Loss on Investment Securities	59,147	0
Increase (Decrease) in Accounts Payable	(1,864)	(132,039)
Increase (Decrease) Unearned Income	(38,814)	168,000
(Increase) Decrease in Accounts Receivable	(16,035)	0
Increase (Decrease) in accrued Expenses	277,550	262,239
(Increase) Decrease in Prepaid Expenses	13,259	(10,000)
Increase in Derivative Expense	(1,395,714)	1,774,213
(Increase) Decrease in Interest Receivable	(1,303)	(9,544)
(Increase) Decrease in Notes Receivable	4,551	0
Increase (Decrease) in Bad Debt Expense	118,121	0
Increase(Decrease) in Bank Overdraft	63	109
Net Cash Provided by (Used in) Operating Activities	(277,537)	(1,030,771)
Cash Flows from Investment Activities
Increase(Decrease) in Sale of Investment Securities	49,858	0
Net Cash Provided By Investment Activities	49,858	0
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	0	25,000
Preferred Stock issued for Cash	0	25,000
Increase (Decrease) in Notes Payable	8,500	(108,128)
Increase in Convertible Notes Payable	226,250	850,000
Net Cash Provided by (Used in) Financing Activities	234,750	791,872
Net Increase (Decrease) in Cash	7,071	(238,899)
Cash at Beginning of Period	8,019	269,973
Cash at End of Period	15,090	31,074
Supplemental Disclosure of Noncash Investing and Financing Activities:
Common Shares Issued for Debt	273,311	131,000
Preferred Shares Issued for Debt	0	0
Cash Paid for Interest	11,520	29,307
Common shares Issued for Interest	28,898	4,662
Preferred Shares issued for Interest	$ 0	$ 0

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and majority owned subsidiary of Regen. Significant inter-company transactions have been eliminated. As of March 31, 2019 Regen owns 82.35% of KCL Therapeutics, Inc. C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. G. DERIVATIVE LIABILITIES The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31, 2019 utilized the following inputs: Risk Free Interest Rate 2.33 % Expected Term 0.01 – 2.1 Yrs Expected Volatility 168.66 – 273.20% Expected Dividends 0 H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2019 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2019 and 2018. K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Mar. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Going Concern

Going Concern	6 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $17,459,047 during the period from April 24, 2012 (inception) through March 31, 2019. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the year ended September 30, 2018 the Company raised $50,000 through the sale of equity securities for cash, $1,382,750 through the sale of convertible notes, and $38,000 through the satisfaction of a Note Receivable issued as consideration for a convertible note issued by the Company. During the quarter ended December 31, 2018 the Company raised $131,250 through the issuance of convertible notes. During the quarter ended March 31, 2019 the Company raised $95,000 through the issuance of convertible notes

Notes Payable, Related Party

Notes Payable, Related Party	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Notes Payable, Related Party	NOTE 4. NOTES PAYABLE , RELATED PARTY March 31, David Koos ( Note 7) 227 Zander Therapeutics, Inc. (Note 7) 8500 Notes Payable, Related Parties $ 8727 $227 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum. As of March 31, 2019 Regen Biopharma Inc. is indebted to ZanderTheraputics, Inc. (“Zander) in the amount of $8,500. On January 10, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable January 10, 2020. On January 14, 2019 Zander loaned $2,000 to Regen. The loan bears simple interest at 10% and is due and payable January 14, 2020. On January 17, 2019 Zander loaned $1,500 to Regen. The loan bears simple interest at 10% and is due and payable January 17, 2020. Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Caven also serve as a Director of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Caven also serve as a Director of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. All of Zander, Regen and KCL Therapeutics are agreeable that Zander shall be permitted at its option to apply any unpaid overdue liability of Regen ( including any and all accrued interest on promissory notes) towards any Anniversary fees and/or Minimum Royalties that may be payable by Zander pursuant to that license agreement originally entered into by Zander and Regen on June 23, 2015 ( Note 7). As of June 30, 2019 Regen is indebted to Zander in the principal amount of $56,900.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2019 $100,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2019 is $0. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of March 31 2019 the unamortized discount on the convertible note outstanding is $0. As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2019 is $0. On September 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2019 is 0. On September 20, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2019 is 0. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $0. As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2019 is 0. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $ 0 As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $0. As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2019 is 0. On December 22, 2016 (“Issue date”) the Company issued a fifth Convertible Note (“Note”) in the face amount of $40,000 for consideration consisting of $40,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.01 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $40,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2019 $40,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2019 is 0. On March 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $75,000 for consideration consisting of $75,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 1, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share . The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31 , 2019 $75,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $214,285 was recognized by the Company as of March 31, 2019. The issuance of the Note amounted in a discount of $75,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $ 23,677. On March 9, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 9, 2020. All or part of the principal is convertible at any time at the demand of the On March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31, 2019 $25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $71,248 was recognized by the Company as of March 31, 2019. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $8,074. On March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share . The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $142,857 was recognized by the Company as of March 31, 2019. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of march 31, 2019 the unamortized discount on the convertible note outstanding is $15,769. On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share . The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”). In the event part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31, 2019 $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $142,857 was recognized by the Company as of March 31, 2019. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2019 the unamortized discount on the convertible note outstanding is $15,422. On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31, 2019 $25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determi

Notes Receivable

Notes Receivable	6 Months Ended
	Mar. 31, 2019
Receivables [Abstract]
Notes Receivable	NOTE 6. NOTES RECEIVABLE March 31, 2019 LG Capital Funding LLC. $ 63,000 $63,000 lent by the Company to LG Capital Funding LLC (“Note Receivable) is due and payable on June 3, 2019 and simple interest at a rate of 8% per annum. The Note Receivable is initially secured by a pledge of a $63,000 Note issued to LG Capital Funding LLC by the Company Adar Alef LLC. $ 50,000 $50,000 lent by the Company to Ader Alef LLC (“Note Receivable) is due and payable on September 22, 2019 and simple interest at a rate of 10% per annum. The Note Receivable is initially secured by a pledge of a $50,000 Note issued to Adar Alef LLC LLC by the Company. Both of the abovementioned Notes Receivable contain provisions allowing the Borrower to cancel payment obligation in the event that the Company becomes noncurrent with regard to the Company’s reporting obligation under the Securities and Exchange Act of 1934. The Company became noncurrent with regard to the Company’s reporting obligation under the Securities and Exchange Act of 1934.as of the due date of the Company’s quarterly report for the Company’s quarter ended march 31, 2019. The Company believes there is a likely chance that the Borrower will cancel their payment obligations under the Notes and has fully reserved the principal amount of the Notes as well as accrued interest earned on the Notes.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS As of September 30, 2018 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by BST Partners on a month to month basis beginning November 1 2018. BST Partners is controlled by David R. Koos who also serves as the Chief Executive Officer of the Company. The sublease is on a month to month basis and rent payable to BST Partners by Regen Biopharma Inc is equal to $5,000 per month. As of March 31, 2018 the Company is indebted to David R. Koos in the amount of $227. $227 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is a subsidiary of Entest Biomedical, Inc. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15 th The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On September 28, 2015 Zander caused to be issued to the Company 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to the Company by Zander as a license initiation fee. Regen Biopharma, Inc. recognized revenue of $192,000 equivalent to the fair value of 8,000,000 of the common shares of Entest Biomedical, Inc as of the date of issuance. During the quarter ended September 30, 2016 Zander paid $17,000 to the Company as a partial payment of the July 15 th, During the quarter ended June 30, 2017 Zander caused to be issued to the Company 83,000 shares of the nonvoting convertible preferred stock of Entest Biomedical, Inc. in satisfaction of 83,000 owed to the Company by Zander.On June 23, 2017 $7,000 of principal indebtedness and $147 of Accrued Interest Payable by the Company to Zander was applied toward the satisfaction of a minimum royalty payment owed by Zander to the Company pursuant to the Agreement. During the quarter ended September 30, 2017 Zander caused to be issued to the Company 102,852 shares of the nonvoting convertible preferred stock of Entest Biomedical, Inc. in satisfaction of $102,852 owed to the Company by Zander. During the quarter ended December 31, 2017 Zander prepaid $58,000 of minimum royalties which will become due pursuant to the Agreement. During the quarter ended March 31, 2018 Zander prepaid $20,000 of minimum royalties which will become due pursuant to the Agreement. On February 7, 2018 the Company and Zande agreed to a 10% reduction of Zander’s June 2018 Annual Anniversary Fee obligation if Zander pays such fee on or before February 10, 2018. $90,000 was paid by Zander in satisfaction of the June 2018 Annual Anniversary Fee during the quarter ended March 31, 2018. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Harry Lander serves as President and Chief Scientific Officer of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Lander and Caven also serve as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.01 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.01 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31, 2019 $11,500 of the principal amount of the Note remains outstanding. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A one time interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of March 31, 2019, 350,000 of the principal amount of the Note remains outstanding. Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Caven also serves as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. On January 10, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable January 10, 2020. On January 14, 2019 Zander loaned $2,000 to Regen. The loan bears simple interest at 10% and is due and payable January 14, 2020. On January 17, 2019 Zander loaned $1,500 to Regen. The loan bears simple interest at 10% and is due and payable January 17, 2020. Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Caven also serve as a Director of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. All of Zander, Regen and KCL Therapeutics are agreeable that Zander shall be permitted at its option to apply any unpaid overdue liability of Regen ( including any and all accrued interest on promissory notes) towards any Anniversary fees and/or Minimum Royalties that may be payable by Zander pursuant to that license agreement originally entered into by Zander and Regen on June 23, 2015 ( Note 7). As of June 30, 2019 Regen is indebted to Zander in the principal amount of $56,900

Accounts Receivable, Related Pa

Accounts Receivable, Related Party	6 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Accounts Receivable, Related Party	NOTE 8. ACCOUNTS RECEIVABLE, RELATED PARTY Accounts Receivable due from Related Party as of June 30, 2019 consist solely of amounts earned by the Company not yet paid resulting from the Company’s license agreement with KCL Therapeutics ( See Note 7) .All of Zander, Regen and KCL Therapeutics are agreeable that Zander shall be permitted at its option to apply any unpaid overdue liability of Regen ( including any and all accrued interest on promissory notes) towards any Anniversary fees and/or Minimum Royalties that may be payable by Zander pursuant to that license agreement originally entered into by Zander and Regen on June 23, 2015 ( Note 7). As of June 30, 2019 Regen is indebted to Zander in the principal amount of $56,900

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9. COMMITMENTS AND CONTINGENCIES On November 16, 2018 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning November 1, 2018. BST is controlled by David Koos, Regen Biopharma, Inc.’s Chairman and Chief Executive Officer.

Stockholders Equity

Stockholders Equity	6 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders Equity	NOTE 10. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of March 31, 2019: Common stock, $ 0.0001 par value; 1, 800,000,000 shares authorized: 377,115,053 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 50,000 shares issued and outstanding as of March 31, 2019, 300,000,000 is designated Series A Preferred Stock of which 150,434,496 shares are outstanding as of March 31, 2019 and 300,000,000 is designated Series M Preferred Stock of which 38,000,000 shares are outstanding as of March 31, 2019. The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. Series AA Preferred Stock On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock"). The Board of Directors of Regen have authorized 300,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

Investment Securities

Investment Securities	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Investment Securities	11. INVESTMENT SECURITIES On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc. On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124. On March 31, 2019 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: Fair Value of Intellectual Property as of 3/31/2019 5,447 Investment Securities as of 3/31/2019 12,250 Note Receivable 8,500 Interest Receivable 8,811 Convertible Note Receivable 350,000 Prepaid Expenses 92,571 Due from Former Employee 4,838 Accounts Payable 1,270,556 Notes Payable 500,000 Accrued Expenses 74,372 Enterprise Value as of 3/31/2019 2,327,345 Less Total Debt (1,844,928 ) Portion of Enterprise Value attributable to shareholders 482,417 Fair Value per share 0.0105948 The abovementioned constitute the Company’s sole investment securities as of March 31, 2019 As of March 31, 2019: 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2019 $ 5,741 $ 4,985 $ (756 ) $ (24546 ) 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2019 $ 13,124 $ 7,681 $ (4551 ) $ (37816 )

Stock Transactions

Stock Transactions	6 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stock Transactions	NOTE 12. STOCK TRANSACTIONS Issuance of Common Shares On January 3, 2019 the Company issued 10585123 common shares in satisfaction of $4607 of convertible indebtedness and $9153 of accrued interest on convertible indebtedness. On January 23, 2019 the Company issued 5774947 common shares in satisfaction of $6770 of convertible indebtedness and $362 of accrued interest on convertible indebtedness. On January 25, 2019 the Company issued 13100000 common shares in satisfaction of $5975 of convertible indebtedness , $500 in fees and $991 of accrued interest on convertible indebtedness. On February 11, 2019 the Company issued 10473668 common shares in satisfaction of $12230 of convertible indebtedness and $704 of accrued interest on convertible indebtedness. On February 15, 2019 the Company issued 13821193 common shares in satisfaction of $15000 of convertible indebtedness and $756 of accrued interest on convertible indebtedness. On February 19, 2019 the Company issued 13790783 common shares in satisfaction of $17500 of convertible indebtedness and $2,220 of accrued interest on convertible indebtedness. On March 1, 2019 the Company issued 8004463 common shares in satisfaction of $8200 of convertible indebtedness and $444 of accrued interest on convertible indebtedness. On March 4, 2019 the Company issued 15000000 common shares in satisfaction of $8756 of convertible indebtedness, $500 in fees and $1543 of accrued interest on convertible indebtedness. On March 19, 2019 the Company issued 12000000 common shares in satisfaction of $5825 of convertible indebtedness, $500 in fees and $874 of accrued interest on convertible indebtedness. On March 19, 2019 the Company issued 16210615 common shares in satisfaction of $13,800 of convertible indebtedness and $2005 of accrued interest on convertible indebtedness. On March 22, 2019 the Company issued 6309524 common shares in satisfaction of $5000 of convertible indebtedness and $300 of accrued interest on convertible indebtedness. Issuance of Series A Preferred Shares On January 9, 2019 the Company issued 10,000,000 Series A Preferred shares to a consultant as consideration for services. Issuance of common shares of KCL Therapeutics, Inc. On January 23, 2019 Dr. Harry Lander and the KCL Therapeutics, Inc (“KCL”) entered into an agreement (“Agreement”) whereby Dr. Lander agreed to provide services as KCL’s Senior Scientific Consultant. Pursuant to the Agreement, Dr. Lander will assist KCL with its development of therapies involving checkpoint NR2F6 therapies. The term of the Agreement is from January 25, 2019 to January 24, 2022 and may be extended by mutual consent. Sole consideration to Dr. Lander for services to be provided pursuant to the Agreement shall be the issuance to Dr. Lander by KCL of 5,000,000 shares of KCL’s common stock. On February 13, 2019 Dr. Lander was issued 5,000,000 of the common shares of KCL. On February 13, 2019 David Koos, the Chairman and Chief Executive Officer of both Regen and KCL, was issued 5,000,000 of the common shares of KCL as consideration for services. On February 13, 2019 Todd Caven, the Chief Financial Officer of both Regen and KCL, was issued 5,000,000 of the common shares of KCL as consideration for services.

Prior Period Adjustments

Prior Period Adjustments	6 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Prior Period Adjustments	NOTE 13. PRIOR PERIOD ADJUSTMENTS The Company has adjusted consulting expenses for the quarter ended March 31, 2018 in the following manner Consulting Expenses reduced by $750. The aforementioned adjustments have resulted in a decrease in Net Loss for the period ended March 31, 2018 as originally reported of $750. The Company has adjusted Dividend Income, Research and Development Expenses, and Consulting Expenses for the quarter ended June 30, 2018 in the following manner: (a) Research and Development Expenses for the period have been increased by $2700 (b) Consulting Expenses for the period have been reduced by $2700 (c) Dividend Income for the period has been increased by $5,741 The aforementioned adjustments have resulted in a decrease in Net Loss for the period ended June 30, 2018 as originally reported of $5,741

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 14. SUBSEQUENT EVENTS On April 2, 2019 the Company issued 12,992,839 common shares in satisfaction of $8,800 of convertible indebtedness and $554 of accrued interest on convertible indebtedness. On May 7, 2019 the Company issued 17,876,797 common shares in satisfaction of $10,000 of convertible indebtedness and $726 of accrued interest on convertible indebtedness. On April 8, 2019 the Company issued 17,971,064 common shares in satisfaction of $12,100 of convertible indebtedness and $1,917 of accrued interest on convertible indebtedness. On April 9, 2019 the Company issued 11,832,569 common shares in satisfaction of $8,000 of convertible indebtedness and $519 of accrued interest on convertible indebtedness. On April 11, 2019 the Company issued 19,472,820 common shares in satisfaction of $14,600 of convertible indebtedness and $588 of accrued interest on convertible indebtedness. On April 18, 2019 the Company issued 14,824,958 common shares in satisfaction of $10,000 of convertible indebtedness and $673 of accrued interest on convertible indebtedness. On April 29, 2019 the Company issued 22,243,153 common shares in satisfaction of $14,800 of convertible indebtedness and $2549 of accrued interest on convertible indebtedness. On May 7, 2019 the Company issued 22,000,000 common shares in satisfaction of $7,948 of convertible indebtedness, $500 in fees and $352 of accrued interest on convertible indebtedness. On June 27, 2019 the Company issued 194,285, 714 shares of the Series A Preferred stock of Regen to Zander Therapeutics in satisfaction of $340,000 of convertible indebtedness. On July 10, 2019 the Company issued 25,870,700 common shares in satisfaction of $2,049 of convertible indebtedness, $500 in fees and $2883 of accrued interest on convertible indebtedness. On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of: $95,000 cash the payment of $5,000 of legal fees The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2020. The Note may be converted into the common stock of Regen at a price per share ( “Conversion Price”) equivalent to 60% of the lowest Trading price of the common stock of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the outstanding shares of the Common Stock of the Company. The proceeds from the issuance of the Note are to be allocated as follows: $30,592 will be utilized to retire the outstanding balance of a $75,000 note issued by the Company on August 15, 2018 to One44 capital, LLC and $22,877 will be allocated to the Company’s accountants and auditors to bring the Company current with regards to the Company’s quarterly reporting requirements under the Securities and Exchange Act of 1934. The Note may be prepaid with the following penalties: Time Period Payment Premium <=60 days after note issuance 125% of the sum of principal plus accrued interest >60 days <= 120 days after note issuance 135% of the sum of principal plus accrued interest >120 days <=180 days after note issuance 140% of the sum· of principal plus accrued· interest This Note may not be prepaid after the 180 th On July 19, 2019 Regen Biopharma, Inc. amended its Certificate of Incorporation increasing its authorized common shares from 1, 800,000,000 with a par value of 0.0001 to 4,800,000,000 with a par value of 0.0001 On July 19, 2019 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $20,331 for consideration consisting of $18,831 cash and payment on behalf of the Company of $1,500 of expenses incurred in connection with the issuance of the Note. The Note pays simple interest in the amount of 8% per annum. The maturity of the Note is July 19, 2019. The Note may be converted into shares of the common stock of Regen at a price per share ( “Conversion Price”) equivalent to 65% of the lowest Trading price of the common stock of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the outstanding shares of the Common Stock of the Company. The Note may be prepaid with the following penalties: Time Period Payment Premium <=60 days after note issuance 115% of the sum of principal plus accrued interest >60 days <= 120 days after note issuance 125% of the sum of principal plus accrued interest >120 days <=180 days after note issuance 135% of the sum· of principal plus accrued· interest This Note may not be prepaid after the 180 th On July 19, 2019 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $14,819 for consideration consisting of $13,319 cash and payment on behalf of the Company of $1,500 of expenses incurred in connection with the issuance of the Note. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2019. The Note may be converted into shares of the common stock of Regen at a price per share ( “Conversion Price”) equivalent to 60% of the lowest Trading price of the common stock of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the outstanding shares of the Common Stock of the Company. The Note may be prepaid with the following penalties: Time Period Payment Premium <=60 days after note issuance 125% of the sum of principal plus accrued interest >60 days <= 120 days after note issuance 135% of the sum of principal plus accrued interest >120 days <=180 days after note issuance 140% of the sum· of principal plus accrued· interest This Note may not be prepaid after the 180 th On July 24, 2019 the Company issued 27,161,700 common shares in satisfaction of $2,962 of convertible indebtedness, $500 in fees and $611of accrued interest on convertible indebtedness. On July 30, 2019 the Company and Auctus Fund, LLC (“Auctus”) agreed to the addition of $9,971 to the remaining balance of that convertible note issued to Auctus on May 18, 2018 in the original principal amount of $114,000 for consideration to the Company of $9,971. On August 13, 2019 David Koos, the Chairman and Chief Executive Officer of Regen Biopharma, Inc. (“Company”) returned 5,000,000 common shares of KCL Therapeutics, Inc. (“KCL”) to KCL for cancellation. On August 13, 2019 Todd Caven , the Chief Financial Officer of the Company returned 5,000,000 common shares of KCL to KCL for cancellation. On August 14 th th As a result of this cancellation, as of August 14 th

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and majority owned subsidiary of Regen. Significant inter-company transactions have been eliminated. As of March 31, 2019 Regen owns 82.35% of KCL Therapeutics, Inc.
USE OF ESTIMATES	C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
PROPERTY AND EQUIPMENT	E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
DERIVATIVE LIABILITIES	G. DERIVATIVE LIABILITIES The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31, 2019 utilized the following inputs: Risk Free Interest Rate 2.33 % Expected Term 0.01 – 2.1 Yrs Expected Volatility 168.66 – 273.20% Expected Dividends 0
INCOME TAXES	H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2019 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2019 and 2018.
NOTES RECEIVABLE	K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any.
REVENUE RECOGNITION	L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
INTEREST RECEIVABLE	M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Derivative Liability	The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31, 2019 utilized the following inputs: Risk Free Interest Rate 2.33 % Expected Term 0.01 – 2.1 Yrs Expected Volatility 168.66 – 273.20% Expected Dividends 0

Notes Payable, Related Party (T

Notes Payable, Related Party (Tables)	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Notes Payable, Related party	March 31, David Koos ( Note 7) 227 Zander Therapeutics, Inc. (Note 7) 8500 Notes Payable, Related Parties $ 8727

Notes Receivable (Tables)

Notes Receivable (Tables)	6 Months Ended
	Mar. 31, 2019
Receivables [Abstract]
Notes Receivable	March 31, 2019 LG Capital Funding LLC. $ 63,000 $63,000 lent by the Company to LG Capital Funding LLC (“Note Receivable) is due and payable on June 3, 2019 and simple interest at a rate of 8% per annum. The Note Receivable is initially secured by a pledge of a $63,000 Note issued to LG Capital Funding LLC by the Company Adar Alef LLC. $ 50,000

Investment Securities (Tables)

Investment Securities (Tables)	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Dividend Income	On March 31, 2019 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: Fair Value of Intellectual Property as of 3/31/2019 5,447 Investment Securities as of 3/31/2019 12,250 Note Receivable 8,500 Interest Receivable 8,811 Convertible Note Receivable 350,000 Prepaid Expenses 92,571 Due from Former Employee 4,838 Accounts Payable 1,270,556 Notes Payable 500,000 Accrued Expenses 74,372 Enterprise Value as of 3/31/2019 2,327,345 Less Total Debt (1,844,928 ) Portion of Enterprise Value attributable to shareholders 482,417 Fair Value per share 0.0105948
Comprehensive Income	The abovementioned constitute the Company’s sole investment securities as of March 31, 2019 As of March 31, 2019: 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2019 $ 5,741 $ 4,985 $ (756 ) $ (24546 ) 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2019 $ 13,124 $ 7,681 $ (4551 ) $ (37816 )

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies (Details)	6 Months Ended
	Mar. 31, 2019
Risk Free Interest Rate	2.33%
Expected Volatility, Minimum	168.66%
Expected Volatility, Maximum	273.20%
Expected Dividends	0.00%
Minimum [Member]
Expected Term	4 days
Maximum [Member]
Expected Term	2 years 1 month 6 days

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Advertising expenses	$ 0	$ 0
Valuation allowance	100.00%
KCL Therapeutics
Ownership Percentage	82.35%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended	86 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception				$ (17,459,047)
Sale of equity securities			$ 50,000
Issuance of convertible debt	$ 95,000	$ 131,250	1,382,750
Satisfaction of Note Receivable			$ 38,000

Notes Payable, Related Party (D

Notes Payable, Related Party (Details)	Mar. 31, 2019USD ($)
Notes Payable, Related Party	$ 8,727
Zander Therapeutics
Notes Payable, Related Party	8,500
David Koos
Notes Payable, Related Party	$ 227

Notes Payable, Related Party _2

Notes Payable, Related Party (Details Narrative) - USD ($)	Jan. 14, 2019	Jan. 10, 2019	Jan. 17, 2019	Mar. 31, 2019	Jun. 30, 2019	Mar. 31, 2018
Zander Therapeutics
Loan	$ 2,000	$ 5,000	$ 1,500
Interest rate	10.00%	10.00%	10.00%
Due date	Jan. 14, 2020	Jan. 10, 2020	Jan. 17, 2020
Indebted Amount				$ 8,500	$ 56,900
David Koos
Note payable				$ 227		$ 227
Interest rate per annum				15.00%

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	6 Months Ended
	Mar. 31, 2019USD ($)
Convertible Note; March 8, 2016
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	8.00%
Maturity Date	Mar. 8, 2019
Beneficial conversion feature	$ 42,600
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	100,000
Cash issued for convertible note	100,000
Convertible Note; April 6, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	8.00%
Maturity Date	Apr. 6, 2019
Beneficial conversion feature	$ 9,900
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note; September 8, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 8, 2017
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Converted value that exceeds the principal if converted into common stock	0
Cash issued for convertible note	50,000
Convertible Note; September 20, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 20, 2017
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Converted value that exceeds the principal if converted into common stock	0
Cash issued for convertible note	50,000
Convertible Note; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Converted value that exceeds the principal if converted into common stock	0
Cash issued for convertible note	50,000
Convertible Note #2; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Converted value that exceeds the principal if converted into common stock	0
Cash issued for convertible note	50,000
Convertible Note #3; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Converted value that exceeds the principal if converted into common stock	0
Cash issued for convertible note	50,000
Convertible Note; December 22, 2016
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 22, 2017
Beneficial conversion feature	$ 40,000
Unamortized discount	0
Outstanding balance	40,000
Converted value that exceeds the principal if converted into common stock	0
Cash issued for convertible note	40,000
Convertible Note; March 1, 2017
Convertible note issued and outstanding	$ 75,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 1, 2020
Unamortized discount	$ 23,677
Outstanding balance	75,000
Derivative Liability	214,285
Cash issued for convertible note	75,000
Convertible Note; March 9, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 9, 2020
Unamortized discount	$ 8,074
Outstanding balance	25,000
Derivative Liability	71,248
Cash issued for convertible note	25,000
Convertible Note; March 13, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 24, 2020
Unamortized discount	$ 15,769
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note: March 31, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 31, 2020
Unamortized discount	$ 15,422
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note; April 19, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Apr. 19, 2020
Unamortized discount	$ 8,827
Outstanding balance	25,000
Derivative Liability	71,429
Cash issued for convertible note	25,000
Convertible Note #2; April 19, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Apr. 19, 2020
Unamortized discount	$ 17,655
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note; May 5, 2017
Convertible note issued and outstanding	$ 200,000
Convertible note, interest rate	10.00%
Maturity Date	May 5, 2020
Unamortized discount	$ 73,540
Outstanding balance	200,000
Derivative Liability	571,429
Cash issued for convertible note	200,000
Convertible Note; May 10, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	May 9, 2020
Unamortized discount	$ 35,251
Outstanding balance	100,000
Derivative Liability	285,714
Cash issued for convertible note	100,000
Convertible Note; May 19, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	May 19, 2020
Unamortized discount	$ 17,655
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note; June 26, 2017
Convertible note issued and outstanding	$ 150,000
Convertible note, interest rate	10.00%
Maturity Date	Jun. 16, 2020
Unamortized discount	$ 61,464
Outstanding balance	150,000
Derivative Liability	428,571
Cash issued for convertible note	150,000
Convertible Note; July 24, 2017
Convertible note issued and outstanding	$ 60,000
Convertible note, interest rate	10.00%
Maturity Date	Jul. 24, 2020
Unamortized discount	$ 16,386
Outstanding balance	60,000
Derivative Liability	171,429
Cash issued for convertible note	60,000
Convertible Note; September 7, 2017
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	8.00%
Maturity Date	Sep. 7, 2018
Unamortized discount	$ 0
Outstanding balance	30,000
Derivative Liability	14,286
Cash issued for convertible note	38,000
Fees	2,000
Convertible Note; August 29, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Aug. 29, 2020
Unamortized discount	$ 11,815
Outstanding balance	25,000
Derivative Liability	71,429
Cash issued for convertible note	25,000
Convertible Note; September 22, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 21, 2020
Unamortized discount	$ 24,703
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note; #2 September 22, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 22, 2020
Unamortized discount	$ 49,452
Outstanding balance	100,000
Derivative Liability	285,714
Cash issued for convertible note	100,000
Convertible Note; September 25, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 25, 2020
Unamortized discount	$ 24,863
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note; October 3, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 3, 2020
Unamortized discount	$ 25,638
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note; October 4, 2017
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 4, 2020
Unamortized discount	$ 20,547
Outstanding balance	40,000
Derivative Liability	114,285
Cash issued for convertible note	40,000
Convertible Note; October 16, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 9, 2020
Unamortized discount	$ 52,463
Outstanding balance	100,000
Derivative Liability	285,714
Cash issued for convertible note	100,000
Convertible Note; November 01, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Nov. 1, 2020
Unamortized discount	$ 13,480
Outstanding balance	25,000
Derivative Liability	71,249
Cash issued for convertible note	25,000
Convertible Note; #2 November 1, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Nov. 1, 2020
Unamortized discount	$ 13,480
Outstanding balance	25,000
Derivative Liability	71,249
Cash issued for convertible note	25,000
Convertible Note; October 9, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 9, 2020
Unamortized discount	$ 51,824
Outstanding balance	100,000
Derivative Liability	285,714
Cash issued for convertible note	100,000
Convertible Note; December 15, 2017
Convertible note issued and outstanding	$ 35,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 15, 2020
Unamortized discount	$ 20,278
Outstanding balance	35,000
Derivative Liability	100,000
Cash issued for convertible note	35,000
Convertible Note; December 20, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 20, 2020
Unamortized discount	$ 58,394
Outstanding balance	100,000
Derivative Liability	258,714
Cash issued for convertible note	100,000
Convertible Note #2; December 20, 2017
Convertible note issued and outstanding	$ 115,000
Convertible note, interest rate	8.00%
Maturity Date	Dec. 6, 2018
Unamortized discount	$ 0
Outstanding balance	63,700
Derivative Liability	70,000
Cash issued for convertible note	100,000
Original Issue Discount	1,750
Fees	13,250
Convertible Note; December 06, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 6, 2020
Unamortized discount	$ 28,558
Outstanding balance	50,000
Derivative Liability	142,857
Cash issued for convertible note	50,000
Convertible Note; January 24, 2018
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 6, 2020
Unamortized discount	$ 14,828
Outstanding balance	25,000
Derivative Liability	71,248
Cash issued for convertible note	25,000
Convertible Note; February 28, 2018
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 28, 2021
Unamortized discount	$ 64,324
Outstanding balance	100,000
Derivative Liability	285,714
Cash issued for convertible note	100,000
Convertible Note; May 18, 2018
Convertible note issued and outstanding	$ 114,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 18, 2019
Unamortized discount	$ 0
Outstanding balance	82,838
Derivative Liability	138,063
Cash issued for convertible note	100,000
Original Issue Discount	14,000
Convertible Note; July 11, 2018
Convertible note issued and outstanding	$ 11,500
Convertible note, interest rate	10.00%
Maturity Date	May 4, 2021
Unamortized discount	$ 8,557
Outstanding balance	11,500
Derivative Liability	32,857
Cash issued for convertible note	11,500
Convertible Note; August 14, 2018
Convertible note issued and outstanding	$ 75,000
Convertible note, interest rate	10.00%
Maturity Date	Aug. 13, 2019
Unamortized discount	$ 30,035
Outstanding balance	46,800
Derivative Liability	65,000
Cash issued for convertible note	71,250
Fees	3,750
Convertible Note; September 30, 2018
Convertible note issued and outstanding	$ 350,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 30, 2020
Beneficial conversion feature	$ 350,000
Unamortized discount	262,859
Converted value that exceeds the principal amount	308,602
Outstanding balance	350,000
Cash issued for convertible note	350,000
Convertible Note; October 3, 2018
Convertible note issued and outstanding	$ 63,000
Convertible note, interest rate	8.00%
Maturity Date	Oct. 3, 2019
Unamortized discount	$ 31,931
Outstanding balance	63,000
Derivative Liability	80,769
Cash issued for convertible note	60,000
Fees	3,000
Convertible Note; #2 October 3, 2018
Convertible note issued and outstanding	$ 63,000
Convertible note, interest rate	8.00%
Maturity Date	Oct. 3, 2019
Unamortized discount	$ 31,931
Outstanding balance	63,000
Derivative Liability	80,769
Cash issued for convertible note	60,000
Convertible Note; October 10, 2018
Convertible note issued and outstanding	$ 75,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 11, 2019
Unamortized discount	$ 39,754
Outstanding balance	75,000
Derivative Liability	104,166
Cash issued for convertible note	71,250
Fees	3,750
Convertible Front End Note; January 22, 2019
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Jan. 22, 2020
Unamortized discount	$ 40,684
Outstanding balance	50,000
Derivative Liability	69,444
Cash issued for convertible note	47,500
Fees	2,500
Convertible Back End Note; January 22, 2019
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Jan. 22, 2020
Unamortized discount	$ 40,684
Outstanding balance	50,000
Derivative Liability	69,444
Cash issued for convertible note	50,000
Convertible Note; February 15, 2019
Convertible note issued and outstanding	50,000
Unamortized discount	43,973
Derivative Liability	69,444
Cash issued for convertible note	47,500
Fees	$ 2,500

Notes Receivable (Details)

Notes Receivable (Details)	Mar. 31, 2019USD ($)
LG Capital Funding LLC
Promissory Note	$ 63,000
Adar Alef LLC
Promissory Note	$ 50,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative)	6 Months Ended
	Mar. 31, 2019USD ($)
LG Capital Funding LLC
Promissory Note	$ 63,000
Interest rate per annum	8.00%
Adar Alef LLC
Promissory Note	$ 50,000
Interest rate per annum	10.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 14, 2019	Jan. 10, 2019	Jan. 17, 2019	Sep. 28, 2015	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 23, 2017
Monthly rent payable to Entest								$ 5,000
License fee				$ 100,000
Royalties receivable, percentage				4.00%
Royalties, receivable				$ 10,000
Common shares issued in satisfaction of license fee				8,000,000
Common shares value in issuance of license initiaion fee				$ 100,000
Revenue recognized equivalent to fair value of common shares				192,000
Partial payment							$ 17,000
Nonvoting convertible preferred stock of Entest Biomedical, Inc issued					102,852	83,000
Debt applied to royalty payment													$ 7,147
Receivable from Zander							$ 17,000				$ 58,000	$ 20,000
Anniversery Fee				$ 100,000
Zander Therapeutics
Loan	$ 2,000	$ 5,000	$ 1,500
Interest rate	10.00%	10.00%	10.00%
Due date	Jan. 14, 2020	Jan. 10, 2020	Jan. 17, 2020
Indebted Amount								8,500		$ 56,900
Convertible Note; September 30, 2018
Convertible note issued and outstanding								$ 350,000
Convertible note, interest rate								10.00%
Outstanding balance								$ 350,000
Convertible Note; July 11, 2018
Convertible note issued and outstanding								$ 11,500
Convertible note, interest rate								10.00%
Maturity Date								May 4, 2021
Outstanding balance								$ 11,500
David Koos
Interest rate per annum								15.00%
Notes Payable, Total amount												227
Note payable								$ 227				$ 227
Convertible Note; March 8, 2016
Capital contributions from related party									$ 728,658
Common shares issued to BMSN									50,010,000
Value of shares issued to BMSN									$ 20,090
Monthly rent payable to Entest									5,000
Anniversery Fee									$ 90,000
Convertible note issued and outstanding								$ 100,000
Convertible note, interest rate								8.00%
Maturity Date									Mar. 8, 2019
Outstanding balance								$ 100,000

Accounts Receivable, Related _2

Accounts Receivable, Related Party (Details Narrative) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Zander Therapeutics
Indebted Amount	$ 56,900	$ 8,500

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	6 Months Ended
	Mar. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Monthly rent payable to Entest	$ 5,000

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	6 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Common stock, Par value	$ 0.0001	$ 0.0001
Common stock, authorized	1,800,000,000	500,000,000
Common stock issued and outstanding	377,115,053	180,315,107
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	800,000,000	800,000,000
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	600,000	600,000
Preferred stock, shares issued	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Preferred shares voting	Series AA Preferred Stock
Series M
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	300,000,000	300,000,000
Preferred stock, shares issued	38,000,000	38,000,000
Preferred stock, shares outstanding	38,000,000	38,000,000
Preferred shares voting	On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock").
Series A
Preferred stock, non-cumulative cash dividends	$ 0.01
Preferred shares voting	Series A Preferred Stock
Series A Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	300,000,000	300,000,000
Preferred stock, shares issued	150,434,496	140,434,496
Preferred stock, shares outstanding	150,434,496	140,434,496

Investment Securities (Details)

Investment Securities (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Prepaid Expenses	$ 101	$ 8,259
Accounts Payable	78,707	$ 80,567
Zander Therapeutics | Common Stock
Fair Value of Intellectual Property	5,447
Investment Securities	12,250
Note Receivable	8,500
Interest Receivable	8,811
Convert Note Receivable	350,000
Prepaid Expenses	92,571
Due from Former Employee	4,838
Accounts Payable	1,270,556
Notes Payable	500,000
Accrued Expenses	74,372
Enterprise Value	2,327,345
Less: Total Debt	(1,844,928)
Enterprise Value available to Shareholders	$ 482,417
Value per Share	$ 0.0105948
Zander Therapeutics | Series M
Fair Value of Intellectual Property	$ 5,447
Investment Securities	12,250
Note Receivable	8,500
Interest Receivable	8,811
Convert Note Receivable	350,000
Prepaid Expenses	92,571
Due from Former Employee	4,838
Accounts Payable	1,270,556
Notes Payable	500,000
Accrued Expenses	74,372
Enterprise Value	2,327,345
Less: Total Debt	(1,844,928)
Enterprise Value available to Shareholders	$ 482,417
Value per Share	$ 0.0105948

Investment Securities (Details

Investment Securities (Details 1) - Zander Therapeutics	6 Months Ended
	Mar. 31, 2019USD ($)
Common Stock
Investment Securities, Basis	$ 5,741
Investment Securities, Fair Value	4,985
Investment Securities, Total Unrealized Gain	(756)
Investment Securities, net Unrealized Gain or (Loss) realized	(24,546)
Series M
Investment Securities, Basis	13,124
Investment Securities, Fair Value	7,681
Investment Securities, Total Unrealized Gain	(4,551)
Investment Securities, net Unrealized Gain or (Loss) realized	$ (37,816)

Investment Securities (Detail_2

Investment Securities (Details Narrative) - Zander Therapeutics - USD ($)	Jun. 11, 2018	Nov. 29, 2018	Mar. 31, 2019
Number of shares issued for property dividend	470,588		470,588
Series M
Number of shares issued in satisfaction of prepaid rent and accrued interest		725,000	725,000
Shares issued in satisfaction of prepaid rent and accrued interest, value		$ 13,124

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	Mar. 04, 2019	Mar. 01, 2019	Feb. 11, 2019	Jan. 09, 2019	Jan. 03, 2019	Mar. 22, 2019	Mar. 19, 2019	Mar. 19, 2019	Feb. 19, 2019	Feb. 15, 2019	Feb. 13, 2019	Jan. 25, 2019	Jan. 23, 2019	Mar. 31, 2019	Sep. 30, 2018
Common stock issued														377,115,053	180,315,107
Chief Executive Officer [Member]
Stock issued for services											5,000,000
Chief Financial Officer [Member]
Stock issued for services											5,000,000
Consultant [Member]
Stock issued for services				10,000,000
Lander [Member]
Common stock issued											5,000,000	5,000,000
Convertible Debt | Common Stock
Shares issued in satisfaction of convertible identedness	15,000,000	8,004,463	10,473,668		10,585,123	6,309,524	12,000,000	16,210,615	13,790,783	13,821,193		13,100,000	5,774,947
Value of shares issued in satisdaction of convertible debt	$ 8,756	$ 8,200	$ 12,230		$ 4,607	$ 5,000	$ 5,825	$ 13,800	$ 17,500	$ 15,000		$ 5,975	$ 6,770
Accrued Interest	1,543	$ 444	$ 704		$ 9,153	$ 300	874	$ 2,005	$ 2,220	$ 756		991	$ 362
Accrued Fees	$ 500						$ 500					$ 500

Prior Period Adjustments (Detai

Prior Period Adjustments (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Equity [Abstract]
Increase in research and development expenses	$ 2,700
Reduction in consulting expenses	2,700	$ 750
Increase in dividend income	5,741
Reduction in Net Loss	$ 5,741	$ 750

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Aug. 14, 2019	Aug. 13, 2019	Jul. 10, 2019	May 07, 2019	May 07, 2019	Apr. 11, 2019	Apr. 09, 2019	Apr. 08, 2019	Apr. 02, 2019	Mar. 04, 2019	Mar. 01, 2019	Feb. 11, 2019	Jan. 03, 2019	Jul. 30, 2019	Jul. 24, 2019	Jul. 19, 2019	Jun. 27, 2019	Apr. 29, 2019	Apr. 18, 2019	Mar. 22, 2019	Mar. 19, 2019	Mar. 19, 2019	Feb. 19, 2019	Feb. 15, 2019	Jan. 25, 2019	Jan. 23, 2019	Mar. 31, 2019	Sep. 30, 2018
Common stock, par value (in dollars per share)																											$ 0.0001	$ 0.0001
Common stock, shares authorized																											1,800,000,000	500,000,000
Convertible Debt | Common Stock
Shares issued in satisfaction of convertible identedness										15,000,000	8,004,463	10,473,668	10,585,123							6,309,524	12,000,000	16,210,615	13,790,783	13,821,193	13,100,000	5,774,947
Value of shares issued in satisdaction of convertible debt										$ 8,756	$ 8,200	$ 12,230	$ 4,607							$ 5,000	$ 5,825	$ 13,800	$ 17,500	$ 15,000	$ 5,975	$ 6,770
Accrued Interest										1,543	$ 444	$ 704	$ 9,153							$ 300	874	$ 2,005	$ 2,220	$ 756	991	$ 362
Accrued Fees										$ 500											$ 500				$ 500
Subsequent Event [Member]
Common stock, par value (in dollars per share)																$ 0.0001
Common stock, shares authorized																4,800,000,000
Subsequent Event [Member] | Convertible Debt | Common Stock
Shares issued in satisfaction of convertible identedness			25,870,700	17,876,797	22,000,000	19,472,820	11,832,569	17,971,064	12,992,839						27,161,700			22,243,153	14,824,958
Value of shares issued in satisdaction of convertible debt			$ 2,049	$ 10,000	$ 7,948	$ 14,600	$ 8,000	$ 12,100	$ 8,800						$ 2,962			$ 14,800	$ 10,000
Accrued Interest			2,883	$ 726	352	$ 588	$ 519	$ 1,917	$ 554						611			$ 2,549	$ 673
Accrued Fees			$ 500		$ 500										$ 500
Subsequent Event [Member] | Convertible Debt | Series A Preferred Stock
Shares issued in satisfaction of convertible identedness																	194,285,714
Value of shares issued in satisdaction of convertible debt																	$ 340,000
Subsequent Event [Member] | Convertible Note; July 19, 2019
Face amount																$ 100,000
Convertible note, interest rate																10.00%
Maturity Date																Jul. 19, 2020
Cash issued for convertible note																$ 95,000
Fees																$ 5,000
Proceeds from issuance note description																$30,592 will be utilized to retire the outstanding balance of a $75,000 note issued by the Company on August 15, 2018 to One44 capital, LLC and $22,877 will be allocated to the Company’s accountants and auditors to bring the Company current with regards to the Company’s quarterly reporting requirements under the Securities and Exchange Act of 1934.
Subsequent Event [Member] | Convertible Note#2; July 19, 2019
Convertible note issued and outstanding																$ 20,331
Convertible note, interest rate																8.00%
Maturity Date																Jul. 19, 2019
Cash issued for convertible note																$ 18,831
Fees																1,500
Subsequent Event [Member] | Convertible Note#3; July 19, 2019
Convertible note issued and outstanding																$ 14,819
Convertible note, interest rate																10.00%
Maturity Date																Jul. 19, 2019
Cash issued for convertible note																$ 13,319
Fees																$ 1,500
Chief Financial Officer [Member]
Number of shares cancelled		5,000,000
Chief Executive Officer [Member]
Number of shares cancelled		5,000,000
Lander [Member]
Number of shares cancelled	5,000,000
Auctus [Member] | Subsequent Event [Member]
Convertible debt description														Company and Auctus Fund, LLC (“Auctus”) agreed to the addition of $9,971 to the remaining balance of that convertible note issued to Auctus on May 18, 2018 in the original principal amount of $114,000 for consideration to the Company of $9,971.